Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
Non-Tubercular Mycobacteria
Have you had success treating localized skin infections due to M. chelonae with single agent therapy in immunocompetent hosts?
Related Questions
Do you recommend prescribing one or two parenteral antibiotics in addition to oral therapy in the management of Mycobacterium abscesses peritonitis related to peritoneal dialysis?
What alternative treatment regimen do you recommend for patients with Mycobacterium kansasii lung infection who can no longer tolerate ethambutol due to drug toxicities?
Do you prolong IV therapy or reduce the number of antibiotic agents for patients with pulmonary NTM infections who have completed induction IV therapy and cannot access oral antibiotic therapy due to cost?
Do you routinely recommend an immunodeficiency work up in patients with ARDS due to influenza infection who develop invasive pulmonary aspergillosis?
Would you treat a brain abscess due to S. anginosus longer than one caused by another organism?
How long do you recommend that a patient wear a mask when resuming biologic infusions following a recent upper respiratory infection?
How long would you wait to place a new bone flap for a patient with C. auris skull osteomyelitis associated with cranioplasty s/p bone flap removal, who is currently on anti-fungal therapy?
What additional treatment strategies would you recommend for a patient with a Mycobacterium chelonae and Mycobacterium abscessus infection following bilateral prophylactic mastectomies and implant insertion, who has undergone multiple surgeries and an extended course of IV antibiotics selected based on sensitivities?
Would you use daptomycin to consolidate therapy in a patient with polymicrobial VRE and rothia bacteremia?
What factors influence your decision to initiate antifungal treatment in asymptomatic lung transplant recipients colonized with Aspergillus?
